Literature DB >> 12694833

Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation.

Michael K M Kam1, Ricky M C Chau, Joyce Suen, Peter H K Choi, Peter M L Teo.   

Abstract

PURPOSE: To compare intensity-modulated radiotherapy (IMRT) with two-dimensional RT (2D-RT) and three-dimensional conformal radiotherapy (3D-CRT) treatment plans in different stages of nasopharyngeal carcinoma and to explore the feasibility of dose escalation in locally advanced disease.
MATERIALS AND METHODS: Three patients with different stages (T1N0M0, T2bN2M0 with retrostyloid extension, and T4N2M0) were selected, and 2D-RT, 3D-CRT, and IMRT treatment plans (66 Gy) were made for each of them and compared with respect to target coverage, normal tissue sparing, and tumor control probability/normal tissue complication probability values. In the Stage T2b and T4 patients, the IMRT 66-Gy plan was combined with a 3D-CRT 14-Gy boost plan using a 3-mm micromultileaf collimator, and the dose-volume histograms of the summed plans were compared with their corresponding 66-Gy 2D-RT plans.
RESULTS: In the dosimetric comparison of 2D-RT, 3D-CRT, and IMRT treatment plans, the T1N0M0 patient had better sparing of the parotid glands and temporomandibular joints with IMRT (dose to 50% parotid volume, 57 Gy, 50 Gy, and 31 Gy, respectively). In the T2bN2M0 patient, the dose to 95% volume of the planning target volume improved from 57.5 Gy in 2D-RT to 64.8 Gy in 3D-CRT and 68 Gy in IMRT. In the T4N2M0 patient, improvement in both target coverage and brainstem/temporal lobe sparing was seen with IMRT planning. In the dose-escalation study for locally advanced disease, IMRT 66 Gy plus 14 Gy 3D-CRT boost achieved an improvement in the therapeutic ratio by delivering a higher dose to the target while keeping the normal organs below the maximal tolerance dose.
CONCLUSIONS: IMRT is useful in treating all stages of nonmetastatic nasopharyngeal carcinoma because of its dosimetric advantages. In early-stage disease, it provides better parotid gland sparing. In locally advanced disease, IMRT offers better tumor coverage and normal organ sparing and allows room for dose escalation.

Entities:  

Mesh:

Year:  2003        PMID: 12694833     DOI: 10.1016/s0360-3016(03)00075-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  85 in total

1.  Analysis of dose-volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT.

Authors:  Gaurav Kumar; Sheh Rawat; Abhishek Puri; Manoj Kumar Sharma; Pranav Chadha; Anand Giri Babu; Girigesh Yadav
Journal:  Jpn J Radiol       Date:  2011-12-14       Impact factor: 2.374

2.  Simultaneous integrated boost intensity-modulated radiotherapy (SIB‑IMRT) in nasopharyngeal cancer.

Authors:  Evangelia Peponi; Christoph Glanzmann; Guntram Kunz; Christoph Renner; Katja Tomuschat; Gabriela Studer
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

3.  Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensity-modulated radiation therapy.

Authors:  Jessica A Lawrence; Lisa J Forrest; Michelle M Turek; Paul E Miller; T Rockwell Mackie; Hazim A Jaradat; David M Vail; Richard R Dubielzig; Richard Chappell; Minesh P Mehta
Journal:  Vet Radiol Ultrasound       Date:  2010 Sep-Oct       Impact factor: 1.363

4.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

Review 5.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

6.  New conformity indices based on the calculation of distances between the target volume and the volume of reference isodose.

Authors:  J M Park; S-Y Park; S-J Ye; J H Kim; J Carlson; H-G Wu
Journal:  Br J Radiol       Date:  2014-09-16       Impact factor: 3.039

Review 7.  Volumetric-modulated arc therapy with RapidArc(®): An evaluation of treatment delivery efficiency.

Authors:  Beatriz E Amendola; Marco Amendola; Naipy Perez; Alejandro Iglesias; Xiaodong Wu
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-17

8.  Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients.

Authors:  Chen Chen; Wei Yi; Jin Gao; Xiao-Hui Li; Lu-Jun Shen; Bo-Fei Li; Zi-Wei Tu; Ya-Lan Tao; Chang-Bin Jiang; Yun-Fei Xia
Journal:  Mol Clin Oncol       Date:  2014-02-20

9.  Radiobiological evaluation of forward and inverse IMRT using different fractionations for head and neck tumours.

Authors:  Brigida C Ferreira; Maria do Carmo Lopes; Josefina Mateus; Miguel Capela; Panayiotis Mavroidis
Journal:  Radiat Oncol       Date:  2010-06-22       Impact factor: 3.481

10.  Dosimetry Comparison between Volumetric Modulated Arc Therapy with Rapid Arcand Fixed Field Dynamic IMRT for Local-Regionally Advanced Nasopharyngeal Carcinoma.

Authors:  Bao-Min Zheng; Xiao-Xia Dong; Hao Wu; Shu-Kui Han; Yan Sun
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.